Background: In light of the poor prognosis for cervical cancer, research continues into the development of innovative and efficacious treatment modalities for this disease. We investigated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) and evaluated its clinical importance in cervical cancer.
introduction
Cervical cancer is the second most common cancer in women worldwide, with 250 000 new cases diagnosed each year [1] . Cervical cancer is the most important manifestation of genital human papillomavirus (HPV) infection, and these viruses encode the E6 and E7 oncogenes involved in cervical cancer [2] . Due to the poor prognosis of cervical cancer, several studies have been carried out to develop more effective treatments for this disease. Along with surgical, radiation and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. It is now widely accepted that new approaches for the treatment of cervical cancer are pivotal to further improve the prognosis of this disease.
The metastatic process involves degradation of the extracellular matrix (ECM), including interstitial basement membranes, by proteinases, which facilitates cell detachment followed by local and systemic spreading. Hepatocyte growth factor (HGF) is a multifunctional growth factor that is secreted by mesenchymal cells in the liver as an inactive single-chain propeptide and normally remains in this form associated with the ECM [3] . It induces the proliferation, motility and morphogenesis of epithelial and endothelial cell types via a high-affinity receptor tyrosine kinase, c-Met [4, 5] . c-Met is known to play important roles in the migration and invasion of tumor cells. Overexpression of c-Met in cervical cancer is associated with cancer progression, and high c-Met expression is correlated with poor survival [6, 7] .
The inactive secreted HGF propeptide is cleaved by HGF activator (HGFA) to achieve its active form. HGFA is regulated by two inhibitors, HGFA inhibitor type I (HAI-1) and type II (HAI-2), which are both type 1 transmembrane proteins with two Kunitz-type serine protease domains in their extracellular portions [8] [9] [10] [11] . Complementary DNA (cDNA) cloning of HAI-2 revealed that this protein is identical to placental bikunin [12] . The two types of HAI identified so far, HAI-1 and HAI-2, both show cell surface expression on epithelial cells. HAI-1 appears to be the cognate inhibitor of HGFA and matriptase [13, 14] , and both HAI-1 and HAI-2 inhibit HGFA and hepsin. HAI-2 is a more efficient inhibitor of hepsin [15] and displays a broader inhibitory spectrum [9, 16] than HAI-1. To date, several studies on HAI-2 expression in tumor tissues have been published. Although initial studies showed that HAI-2 expression was upregulated in pancreatic cancer [11] , other studies demonstrated marked downregulation in glioblastoma, hepatocellular carcinoma and renal carcinoma, which was partly due to hypermethylation of the HAI-2 promoter region [17] [18] [19] . However, the issues of whether HAI-2 is correlated with cervical cancer and its mechanisms of action in this disease remain unclear. In the current study, we examined whether HAI-2 protein expression is correlated with the clinicopathological characteristics of patients with cervical cancer. The main aim of the study was to determine whether HAI-2 protein could be used as a favorable prognosis marker for patients with cervical cancer. Our data clearly indicated that overexpression of HAI-2 inhibited cell growth and promoted apoptosis. Thus, we propose that HAI-2 may represent a potential target for gene therapy of cervical cancer.
patients and methods

patients and tissues
The patient population consisted of 52 patients presenting with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIB cervical cancers. Each of these patients underwent radical hysterectomy and pelvic lymphadenectomy at the Department of Obstetrics and Gynecology of Okayama University Hospital. Patients with neo-adjuvant chemotherapy were excluded from this study. Tumor specimens were obtained at the time of surgery, immediately fixed in 10% neutral-buffered formalin and then embedded in paraffin. The histological cell types were classified according to the World Health Organization classification as follows: 27 squamous cell carcinomas, 18 adenocarcinomas and seven adenosquamous carcinomas. Clinical staging was assessed based on the FIGO staging system as follows: 22 stage IB cancers, three stage IIA cancers and 27 stage IIB cancers. The median age at the time of surgery was 46 years (range 27-66 years). Patients with lymph node metastasis, parametrial involvement, deep stromal invasion or marked lymph-vascular space involvement were treated with adjuvant external whole-pelvic irradiation or chemoradiation (n = 19) or chemotherapy (n = 11). The disease-free survival (DFS) and overall survival (OS) rates were defined as the intervals from the initial surgery to clinically or radiologically proven recurrence and death, respectively. The end date of the follow-up study for conducting the analysis was 31 July 2006, and the median duration of the follow-up was 77 months (range 4-146).
immunohistochemical analysis and staining evaluation
Formalin-fixed paraffin-embedded 4-lm sections were deparaffinized with xylene and rehydrated in ethanol. Endogenous peroxidase activity was quenched by treatment with methanol containing 0.3% hydrogen peroxidase for 15 min. Next, the sections were incubated with an anti-HAI-2 primary antibody at room temperature, followed by staining with a streptavidin-biotin-peroxidase kit (Nichirei, Tokyo, Japan). The sections were counterstained with hematoxylin. The levels of HAI-2 staining in the tumors were classified into three groups by scoring the percentages of positively stained cells: 2, strong staining, >50% of cells; 1, moderate staining, 10%-50% of cells and 0, weak staining, <10% of cells. Two independent examiners with no prior knowledge of the patients' clinical data conducted the microscopic evaluations. Controversial cases were evaluated using a conference microscope.
cell culture, media and generation of transfectants The HPV 18 type HeLa (ATCC no. CCL-2) and HPV 16 type SiHa cancer cell lines examined were derived from human cervical carcinomas. The SiHa and HeLa cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) at 37°C in an atmosphere of 5% CO 2 in air. A cDNA encoding the whole coding region of HAI-2 was constructed by PCR using a full-length HAI-2 cDNA as a template. The primers used for HAI-2 were 5#-AGCTCTAGAGCC ATGGCGCAGCTGTGCGG-3# and 5#-TTAGTC-GACTCACAGGACATATGTGTTCTTC-3#. The restriction sites XBaI and SalI present in the primers were used for subcloning into the pCIneo expression vector (Promega, Madison, WI) to generate the expression vector pCI-HAI-2. The HAI-2 cDNA expression vector was transfected into the two cervical cancer cell lines using the TransFast transfection reagent (Promega, Madison, WI). Mock transfected cells served as a control.
western blotting analysis
Cell lysates were collected and estimated using a Protein Assay System (BioRad, Hercules, CA) according to the manufacturer's protocols. Proteins from each cell line were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. The polyclonal and monoclonal antibodies used for immunoblotting were as follows: anti-HAI-2, anti-matriptase, anti-Bcl-2 and anti-Bak (Santa Cruz Biotechnology, Santa Cruz, CA); anti-hepsin (Cayman Chemical, Ann Arbor, MI) and anti-b-actin (Sigma Chemical Co., St Louis, MO). The working dilution of all the primary antibodies was 1 : 1000. After incubation of the membranes with appropriate secondary antibodies, antigen-antibody complexes were detected using an enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, NJ).
cell viability assay
To examine the cell viabilities after transient transfection of the HAI-2 vector into the SiHa and HeLa cervical cancer cell lines, SYTO 10 green fluorescent nucleic acid stain and Dead Red (ethidium homodimer-2) nucleic acid stain (Live/DeadÒ Reduced Biohazard Viability/Cytotoxicity Kit; Invitrogen, Eugene, OR) were added to each well and incubated for 15 min. Cell fluorescence was observed under a fluorescence microscope (Olympus, Tokyo, Japan).
Matrigel invasion assay
To investigate differences in the invasive abilities of cells expressing HAI-2, we used BioCoat Matrigel Invasion Chambers (BD Bioscience, Bedford, MA). SiHa and HeLa cervical cancer cells with or without transient transfection of the HAI-2 vector were incubated in situ with 10 lg/ml of DiI (Invitrogen) in DMEM containing 10% FBS for 1 h. The labeled cells (5 · 10 4 ) of each genotype were then added to the chambers inserts, and 0.75 ml of medium was added to the bottom of each well. After 48 h of incubation, the membranes were removed from the inserts and mounted on slides, and the numbers of invading cells were counted under a microscope. The Matrigel assays were carried out in triplicate.
MTS assay and fluorescein isothiocyanate-conjugated annexin V
The effects of HAI-2 on cell proliferation were evaluated using the MTS assay (Promega). Cells were seeded into 96-well plates and cultured until the cell density reached 5 · 10 4 cells/well. The cells were then transiently transfected with the HAI-2 vector for 12, 24, 36 or 48 h. After incubation with MTS for 1 h, the absorbances were measured at a wavelength of 490 nm using an ELISA plate reader (Bio-Rad Systems, Hercules, CA). In addition, apoptosis was measured by staining with fluorescein isothiocyanate (FITC)-conjugated annexin V using a MEBCYTO Apoptosis Kit (MBL, Nagoya, Japan) according to the manufacturer's recommendations and flow cytometric analysis.
cell growth in monolayers Table 1 shows the distribution of cases scored as positive for each of the biological parameters examined, according to the clinicopathological characteristics in the overall population. As expected, significant associations were found between HAI-2 expression and clinicopathological parameters such as stage (P = 0.017), lymph node metastasis (P = 0.005) and ovarian metastasis (P = 0.038), while no associations were detected for age, histological type, tumor size, stromal invasion, vaginal invasion, parametrial invasion or lymph-vascular involvement (Mann-Whitney U test, P < 0.05).
univariate survival analysis
The results of univariate survival analyses of the other variables are shown in Table 2 . Overall, HAI-2 was most significantly identified in DFS and OS analyses as a prognostic factor for cervical cancer using the log-rank test. The DFS and OS curves of the 52 cervical cancer patients according to their HAI-2 expression status are shown in Figure 2A and B, respectively. The DFS and OS rates of patients exhibiting high HAI-2 expression (score of 2) were significantly higher than those of patients exhibiting low HAI-2 expression (scores of 0 or 1) (P = 0.016 and 0.021, respectively, Mann-Whitney U test).
western blot assay
The functional roles of HAI-2 were examined by transient transfection of a HAI-2 vector followed by western blotting ( Figure 3A 
Matrigel invasion assay
We assessed the motility and invasiveness of SiHa and HeLa cells overexpressing HAI-2 using BioCoat Matrigel Invasion Chambers. Cells were plated on the upper surface of each membrane and cultured for 48 h. Next, the cells invading to the bottom side of each membrane were stained and counted. The percentages of cells reaching the bottom of the filter were decreased to 31.8% and 25.8% at 48 h after transient transfection of the HAI-2 vector into SiHa and HeLa cells, respectively ( Figure 4A ).
MTS and FITC-conjugated annexin V assays
Previous reports have shown that HAI-2 acts during apoptosis in ovarian cancer [20, 21] . We used MTS and FITC-conjugated annexin V assays to examine apoptosis after transient transfection of the HAI-2 vector into SiHa and HeLa cervical cancer cell lines. Transient transfection of the HAI-2 vector resulted in significant cell growth inhibition of these cell lines, as evaluated by the MTS assay ( Figure 4B ). Furthermore, flow cytometric data revealed that transient transfection of the HAI-2 vector for 48 h increased the FITC-annexin V-positive and propidium iodide-positive signals ( Figure 4C ), indicating that HAI-2 induced apoptosis in these cell lines. HAI-2 increased the total percentages of apoptotic and necrotic cells to We also investigated the effects of HAI-2 overexpression on the protein levels of apoptotic molecules, namely the antiapoptotic Bcl-2 and proapoptotic Bak. As shown in Figure 5A , the level of Bak protein expression was upregulated while that of Bcl-2 protein expression was downregulated in the SiHa and HeLa cell lines following transient transfection of the HAI-2 vector.
cell growth in monolayers and anchorageindependent cell growth in soft agar
The effects of HAI-2 overexpression on cell proliferation were analyzed using transient transfection of the HAI-2 vector into the SiHa and HeLa cell lines. Significant inhibitory effects of HAI-2 on the cell growth were observed following transient transfection of the HAI-2 vector into both SiHa and HeLa cells compared with the control cells (P < 0.05; Figure 5B ). Furthermore, colony formation assays following transient transfection of the HAI-2 vector into SiHa and HeLa cells revealed significantly reduced numbers of colonies compared with control cells (P < 0.01; Figure 5C ). discussion This is the first study to examine HAI-2 protein expression in human cervical cancer specimens. HAI-2 is a Kunitz-type serine protease inhibitor that has a broad inhibitory spectrum against serine proteases. It has been reported that reduced expression of HAI-2 is possibly involved in disease progression in glioblastoma, hepatocellular carcinoma and renal carcinoma [17] [18] [19] . In the current study, we examined whether HAI-2 protein expression was correlated with clinicopathological characteristics in patients with cervical cancer. Immunohistochemistry of cervical cancer specimens from chemonaive patients revealed decreased HAI-2 protein expression with increasing stage, lymph node metastasis and ovarian metastasis. Interestingly, a low level of HAI-2 immunostaining was significantly associated with a poor prognosis in cervical cancer. Taken together, these findings indicate that HAI-2 protein could be an important factor for identifying cervical cancer patients with a favorable prognosis. However, the mechanism of action of HAI-2 in cervical cancer remains unclear.
HAI-2 is an endogenous inhibitor of matriptase and hepsin. Matriptase and hepsin are both type 2 transmembrane proteins with an extracellular serine proteinase domain and show enhanced expression in a variety of tumor tissues [22] . 
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Matriptase has been proposed to initiate signaling and proteolytic cascades through its ability to activate prourokinase and protease-activated receptor 2 [23, 24] , while hepsin is thought to be involved in activating the coagulation cascade [25] . In the present study, we found that hepsin and matriptase were significantly inhibited by HAI-2 in cervical cancer cell lines. Several previous reports have also shown that HAI-2 acts during apoptosis [20, 21] . Indeed, HAI-2 was found to induce apoptosis in the cervical cancer cell lines examined in the present study. To trace the steps in the apoptotic cascade, we evaluated the activation of the proapoptotic protein Bak and antiapoptotic protein Bcl-2 [26, 27] . HAI-2 was found to upregulate Bak protein expression and downregulate Bcl-2 expression in the cervical cancer cell lines examined, thereby inducing apoptosis. Overall, HAI-2 shows potential inhibitory effects mediated by reductions in hepsin and matriptase expression, which lead to apoptosis by increasing the level of Bak and reducing the level of Bcl-2.
Cervical cancer is the most important manifestation of genital HPV infection, and these viruses encode the E6 and E7 oncogenes, which are essential for malignant transformation as well as maintenance of the malignant phenotype of cervical cancer [2] . The E6 and E7 proteins of HPV become immortalized, at least in part, and prevent inactivation of the tumor suppressor protein p53 and retinoblastoma protein (RB) [28] . These tumor suppressor proteins also regulate the expression of proangiogenic and antiangiogenic factors by cells. For this reason, experiments were conducted to determine the effects of HAI-2 on the p53 and RB proteins. However, HAI-2 was not correlated with the levels of the p53 tumor suppressor protein or cell cycle regulatory RB protein (data not shown).
In summary, in vitro and in vivo studies have revealed a critical role for HAI-2 in disruption of the basement membrane in cervical cancer. The present findings identify HAI-2 as a favorable prognostic marker for cervical cancer. We 
